Feasibility study to evaluate capabilities for conducting psychiatric clinical research within the Rwandan mental healthcare system
Conclusions
This work was designed to strengthen global research in schizophrenia by building the capacity of researchers to prepare and conduct pharmaceutical trials in resource-limited settings. Although the study was ended early, modifications motivated by the results will facilitate the successful design and completion of more comprehensive studies, including an ongoing, follow-up interventional trial of PP1M/PP3M in a larger population of patients in Rwanda.
Trial registration number
NCT03713658
Source: BMJ Open - Category: General Medicine Authors: Alphs, L., Turkoz, I., Smith-Swintosky, V., Keenan, A., Abraham, E., Schotte, A., Hooker, E., Damascene Iyamuremye, J., Kayiteshonga, Y., Bizoza, R., Mancevski, B. Tags: Open access, Mental health Source Type: research
More News: Clinical Trials | General Medicine | Invega | Invega Sustenna | Men | Psychiatry | Risperdal Consta | Rwanda Health | Schizophrenia | Study | Training | Universities & Medical Training